{
  "eval_id": "S33",
  "timestamp": "2025-09-19T09:04:14.740462+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "In a scenario where a patient with HR+/HER2- breast cancer has progressed after CDK4/6 inhibitors, itâ€™s important to consider the next line of therapy based on the latest evidence. Look at options like endocrine therapy with everolimus or chemotherapy, depending on their performance status and disease burden. Always ensure to discuss potential side effects and efficacy as outlined in the SmPC. Please email me the SmPC for more detailed guidance."
}